• FDA approves 1st gene therapy for hemophilia A

    The FDA approved the first gene therapy treatment for adults with severe hemophilia A.
  • Leiters rebrands to focus on expansion

    Leiters, an FDA registered provider of sterile pharmacy services based in Englewood, Colo., announced the company's rebranding to Leiters Health to focus on expanding in the healthcare market.
  • Trial for 1st fully AI-generated drug underway

    Insilico Medicine, a biotech company based in Hong Kong, created the first drug generated entirely by artificial intelligence to successfully reach clinical testing on humans, CNBC reported June 29.
  • 1st gene therapy for severe hemophilia A approved

    BioMarin Pharmaceutical attained the first FDA approval for a gene therapy indicated to treat severe hemophilia A.
  • Menopause drug linked to dementia

    Researchers confirmed a link between the use of menopause hormonal therapies and dementia and Alzheimer's, but they could not determine the cause, according to a study published June 28 in BMJ.
  • Ballad taps AI to prevent medication errors

    Johnson City, Tenn.-based Ballad Health is using artificial intelligence to identify potential medication errors and improve pharmacy workflows, the health system said June 29.
  • 4 notes from Wolters Kluwer on prepping pharmacists for the future

    Convenience and cost-saving are priorities of American consumers, particularly for those who belong to Gen Z and Millennial generations, and a recent Wolters Kluwer survey found that the same goes for how they feel about prescriptions.
  • 8 recent moves from Mark Cuban Cost Plus Drugs

    In the last 30 days, Mark Cuban Cost Plus Drug Co. has spread its affiliate pharmacy network to 12 states and secured three partnerships.
  • FDA warns wholesaler over counterfeit drugs

    The FDA has issued a warning to wholesale drug distributor Safe Chain Solutions over four major violations — including ones related to counterfeit and unapproved drugs — which the agency found after an inspection it conducted between April and May.
  • Viewpoint: Future pharmacists will fill care gaps, take on more leadership roles

    The pharmacists of tomorrow will be "stepping into the gap where physicians have previously operated," Steve Martin, PharmD, dean of Ohio Northern University's Raabe College of Pharmacy in Ada, said in a June 26 release.
  • 礼来公司的肥胖药物指出24.2%的平均重量t loss

    Eli Lilly's investigational obesity drug reduced phase 2 study participants' weight by 24.2 percent after nearly a year's worth of treatment, marking more significant weight loss results compared to other drugs currently being studied or on the market.
  • Binghamton University claims best pharmacy residency match in nation

    Seniors in Binghamton (N.Y.) University’s School of Pharmacy and Pharmaceutical Sciences program had the best Phase 1 match rate of any pharmacy residency applicants in the country at a rate of 96 percent, according to a June 27 news release.
  • Oncology group revises guidance amid cancer drug shortage

    With about a dozen cancer drugs on back order and no clear end to the shortages, the American Society of Clinical Oncology and the Society of Gynecologic Oncology recently advised clinicians to ration chemotherapy supplies.
  • Washington State U lowers some PharmD students' tuition by $12K

    Pullman-based Washington State University reduced out-of-state tuition for students working toward their Doctor of Pharmacy degree by 30 percent, or about $12,000, with the hopes "to remedy the acute pharmacist shortage in the state."
  • 7 drugs now in shortage

    Of the hundreds of ongoing drug shortages in the U.S., some are lifesaving cancer medications and 14 are among the 20 most commonly prescribed.
  • Pfizer cancels obesity drug trial

    Pfizer discontinued its research into the obesity drug candidate lotiglipron after phase 1 and 2 studies found elevated transaminases, or liver enzymes, in participants, the drugmaker said June 26.
  • FDA grants fast-track designation to new flu prevention drug

    The FDA has given a fast-track designation to a drug designed to prevent infection from both influenza A and B strains created by San Diego-based Cidara Therapeutics, according to a June 22 news release.
  • FDA approves 1st gene therapy for Duchenne muscular dystrophy

    The FDA approved the first gene therapy for some pediatric patients with Duchenne muscular dystrophy, a rare genetic condition that weakens the body's muscles, on June 22.
  • CDC panel greenlights RSV shot for older adults

    People 60 and older "may" get a respiratory syncytial virus vaccine — that is what a CDC advisory panel voted June 21, stopping short of what was anticipated to be a stronger recommendation that older adults "should" get the shots.
  • New Hampshire hospital fined $2M in missing fentanyl case

    Keene, N.H.-based Cheshire Medical Center will pay $2 million in connection with an incident in which gallons of fentanyl solution were lost or unaccounted for in a four-month period.